Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ABUSNASDAQ:DAWNNASDAQ:GYRENASDAQ:RTTR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABUSArbutus Biopharma$3.53-1.4%$3.30$2.71▼$4.73$676.09M1.23968,171 shs507,721 shsDAWNDay One Biopharmaceuticals$6.67-0.3%$6.89$6.08▼$16.76$676.09M-1.31.13 million shs1.16 million shsGYREGyre Therapeutics$7.99-1.0%$9.08$6.11▼$19.00$749.13M1.79123,474 shs145,090 shsRTTRRitter Pharmaceuticals$3.71-2.9%$2.99$0.15▼$1.27$171.32M-0.4314.23 million shs6,381 shsThese 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABUSArbutus Biopharma0.00%+1.44%+14.61%+7.62%+12.42%DAWNDay One Biopharmaceuticals0.00%-7.23%+6.72%-23.07%-47.11%GYREGyre Therapeutics0.00%-4.99%-29.60%-34.93%-27.63%RTTRRitter Pharmaceuticals0.00%-1.01%-5.79%+21.31%+1,765.33%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationABUSArbutus Biopharma2.2202 of 5 stars3.50.00.00.03.22.50.6DAWNDay One Biopharmaceuticals1.4998 of 5 stars3.60.00.00.01.62.50.0GYREGyre Therapeutics0.3056 of 5 stars0.03.00.00.02.00.80.0RTTRRitter PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceABUSArbutus Biopharma 3.00Buy$5.5055.81% UpsideDAWNDay One Biopharmaceuticals 3.13Buy$30.57358.34% UpsideGYREGyre Therapeutics 3.00BuyN/AN/ARTTRRitter Pharmaceuticals 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest RTTR, GYRE, DAWN, and ABUS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/7/2025DAWNDay One BiopharmaceuticalsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$25.005/7/2025DAWNDay One BiopharmaceuticalsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$30.00 ➝ $27.004/3/2025DAWNDay One BiopharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$36.00 ➝ $36.003/28/2025ABUSArbutus BiopharmaChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$5.00 ➝ $5.003/25/2025DAWNDay One BiopharmaceuticalsThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$39.00 ➝ $27.00(Data available from 6/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookABUSArbutus Biopharma$6.40M105.59N/AN/A$0.63 per share5.60DAWNDay One Biopharmaceuticals$161.92M4.18N/AN/A$3.98 per share1.68GYREGyre Therapeutics$100.64M7.44$0.16 per share50.49$0.18 per share44.39RTTRRitter PharmaceuticalsN/AN/AN/AN/A$0.10 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateABUSArbutus Biopharma-$72.85M-$0.41N/AN/AN/A-1,137.65%-68.18%-51.55%7/30/2025 (Estimated)DAWNDay One Biopharmaceuticals-$188.92M-$0.71N/AN/AN/AN/A-22.40%-19.79%7/8/2025 (Estimated)GYREGyre Therapeutics-$92.93M$0.02399.50∞N/A-84.57%-118.43%-71.97%8/12/2025 (Estimated)RTTRRitter Pharmaceuticals-$10.13MN/AN/A∞N/AN/AN/A-162.05%N/ALatest RTTR, GYRE, DAWN, and ABUS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2025Q1 2025ABUSArbutus Biopharma-$0.09-$0.13-$0.04-$0.13$2.54 million$1.76 million5/9/2025Q1 2025GYREGyre Therapeutics$0.03$0.03N/AN/A$28.40 million$22.06 million5/6/2025Q1 2025DAWNDay One Biopharmaceuticals-$0.46-$0.35+$0.11-$0.35$30.28 million$30.76 million3/27/2025Q4 2024ABUSArbutus Biopharma-$0.08-$0.07+$0.01-$0.07$2.20 million$1.57 million3/17/2025Q4 2024GYREGyre Therapeutics$0.04$0.01-$0.03$0.02$23.50 million$27.87 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthABUSArbutus BiopharmaN/AN/AN/AN/AN/ADAWNDay One BiopharmaceuticalsN/AN/AN/AN/AN/AGYREGyre TherapeuticsN/AN/AN/AN/AN/ARTTRRitter PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioABUSArbutus BiopharmaN/A7.027.02DAWNDay One BiopharmaceuticalsN/A14.6214.55GYREGyre TherapeuticsN/A3.723.29RTTRRitter PharmaceuticalsN/A3.673.67Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipABUSArbutus Biopharma43.79%DAWNDay One Biopharmaceuticals87.95%GYREGyre Therapeutics23.99%RTTRRitter Pharmaceuticals0.84%Insider OwnershipCompanyInsider OwnershipABUSArbutus Biopharma20.30%DAWNDay One Biopharmaceuticals6.20%GYREGyre Therapeutics10.00%RTTRRitter Pharmaceuticals15.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableABUSArbutus Biopharma90191.53 million181.91 millionOptionableDAWNDay One Biopharmaceuticals60101.36 million92.38 millionOptionableGYREGyre Therapeutics4093.76 million75.27 millionNo DataRTTRRitter Pharmaceuticals746.15 millionN/ANot OptionableRTTR, GYRE, DAWN, and ABUS HeadlinesRecent News About These CompaniesRochester football bows to St. Louis Cardinal Ritter in battle of state championsOctober 4, 2024 | sj-r.comScott Ritter claims search of home is related to 'foreign agent’ lawAugust 9, 2024 | timesunion.comFBI raids NY home of ex-UN weapons inspector Scott RitterAugust 9, 2024 | nypost.comJohn Ritter Biography & MoviesMay 22, 2024 | tribute.caJeff RitterApril 19, 2024 | si.comDr. John D. RitterJanuary 24, 2024 | health.usnews.comGerman chocolate war ends with Ritter Sport victoryOctober 28, 2023 | politico.euKristen RitterSeptember 15, 2023 | health.usnews.comOp-ed column: Sandusky sex charges contrast with setup against Scott RitterJuly 8, 2023 | dailygazette.comScott Ritter arrested in Pennsylvania on child sex chargesJuly 8, 2023 | dailygazette.comDr. Harold K. RitterJuly 8, 2023 | health.usnews.comDenver Business Journal welcomes new tech reporterJuly 1, 2023 | bizjournals.comGary W. Ritter, Ph.D.June 16, 2023 | slu.eduJason Ritter and Drew Barrymore's raw conversation on her show may matter more than you thinkApril 10, 2023 | usatoday.comRitter Pharmaceuticals Changing the Game With Lactose Intolerance TreatmentMarch 29, 2023 | thestreet.comGlobal Microbiome Market Report 2023: Major Players Include MicroBiome Therapeutics, Seres Therapeutics, Enterome Bioscience and Second GenomeMarch 18, 2023 | finance.yahoo.comMelanie Lynskey's husband Jason Ritter will join her in Yellowjackets this seasonJanuary 19, 2023 | yahoo.comRitter Public Library in Vermilion adds book clubJanuary 15, 2023 | morningjournal.comMicrobiome Clinical Trial Pipeline Space Brims with Novel Emerging Therapies with 130+ Key Players Working in the Domain | DelveInsightNovember 16, 2022 | finance.yahoo.comBurlington freshman Olivia Ritter hits to pool as Olivia Kraus climbs out of the waterOctober 1, 2022 | thehawkeye.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeRTTR, GYRE, DAWN, and ABUS Company DescriptionsArbutus Biopharma NASDAQ:ABUS$3.53 -0.05 (-1.40%) Closing price 06/13/2025 04:00 PM EasternExtended Trading$3.60 +0.08 (+2.12%) As of 06/13/2025 05:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of imdusiran (AB-729), a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression. The company's research and development programs include AB-101, an oral PD-L1 inhibitor to reawaken patients' HBV-specific immune system; and small molecule antiviral medicines to treat coronaviruses, including COVID-19. It has licensing agreements with Gritstone Oncology, Inc; Alnylam Pharmaceuticals, Inc.; Qilu Pharmaceuticals Co, Ltd; Assembly Biosciences, Inc.; Acuitas Therapeutics, Inc.; and Antios Therapeutics, Inc. Arbutus Biopharma Corporation also has a clinical collaboration agreement with Barinthus Biotherapeutics plc to evaluate VTP-300. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania.Day One Biopharmaceuticals NASDAQ:DAWN$6.67 -0.02 (-0.30%) Closing price 06/13/2025 04:00 PM EasternExtended Trading$6.72 +0.04 (+0.67%) As of 06/13/2025 07:24 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Brisbane, California.Gyre Therapeutics NASDAQ:GYRE$7.99 -0.08 (-0.99%) Closing price 06/13/2025 04:00 PM EasternExtended Trading$8.14 +0.15 (+1.93%) As of 06/13/2025 06:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Gyre Therapeutics, Inc., a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases. In addition, it advances a product pipeline in China, including Pirfenidone, for dermatomyositis interstitial lung disease, systemic sclerosis-associated interstitial lung disease, and pneumoconiosis, as well as for diabetic kidney disease; and product candidates for acute-on-chronic liver failure, chronic obstructive pulmonary disease, and pulmonary arterial hypertension. The company was founded in 2002 and is headquartered in San Diego, California.Ritter Pharmaceuticals NASDAQ:RTTRRitter Pharmaceuticals, Inc. develops and sells novel therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases. Its lead product candidate is RP-G28, a novel microbiome modulator, which has completed Phase 2b clinical trial for the reduction of symptoms associated with lactose intolerance. The company's product, RP-G28 is designed to stimulate the growth of lactose-metabolizing bacteria in the colon, thereby adapting the gut microbiome to assist in digesting the lactose that reaches the large intestine. The company was formerly known as Ritter Natural Sciences, LLC and changed its name to Ritter Pharmaceuticals, Inc. in September 2008. Ritter Pharmaceuticals, Inc. was founded in 2004 and is headquartered in Los Angeles, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/09 - 06/13 Alphabet Enters a Bull Market: Is It Time to Buy? Ouster Soars 27% as DoD Grants First 3D LiDAR Approval for Drones RH Stock Rockets on Surprise Profit and Tariff Shift Super Micro Computer Stock: 2 Levels Smart Money Is Watching Intel's Price Spikes: Noise, or the First Notes of a Turnaround? IBM Up 10 Days in a Row: What’s Driving the Winning Streak? SoFi Stock’s Next Test: Can It Justify Its Premium Valuation? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
